CHEK1 and prostate carcinoma: Inhibition of CDC6 expression together with a Chk1/2 inhibitor, could reduce TopBP1 protein levels and ATR S428 and Cdc25C S216 phosphorylation, which results in inhibiting ATR-Chk1 signalling and synergistically increasing treatment efficacy in prostate cancer [9].